On September 23, researchers highlighted a significant dietary risk for children taking GLP-1 receptor agonists. An analysis of claims records revealed that 16.8% of pediatric patients developed GLP-1 nutritional deficiencies within twelve months of initiating pharmacotherapy for weight or diabetes management.
Missing Dietary Interventions
The retrospective review examined over 2,000 youths aged 10 to 17 taking drugs like liraglutide, dulaglutide, and semaglutide between 2017 and 2022. Despite the appetite-suppressing nature of these medications during vital developmental stages, clinical follow-up for diet was alarmingly low. Scientists noted that a mere 5% of young users were provided with dietary counseling in the initial 30 days of treatment, climbing to just under a quarter by the six-month mark.
Protecting Skeletal Health
The most frequent issue observed was a lack of adequate vitamin D, which impacted 12.4% of the analyzed group. Dr. Justin Ryder, the study’s senior author from the Ann & Robert H. Lurie Children’s Hospital of Chicago, emphasized that maintaining sufficient levels of calcium, iron, and vitamin D is imperative to support adolescent bone maturation and biological changes.
Rather than waiting for clinical signs of malnourishment, the research team urges medical professionals to incorporate dietetic support at the very start of a prescription protocol. Integrating immediate counseling can help safeguard developing bodies against the unintended nutritional consequences of powerful metabolic therapies.